Clinical trials: Malignant Tumor Liver
Hepatocellular Carcinoma
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
This study will evaluate the safety, tolerability, pharmacokinetic and efficacy of fisogatinib (formerly known as BLU-554) in combination with CS1001 in patients with locally advanced or metastatic hepatocellular carcinoma (HCC)
- Trial name
- NCT04194801
- Testing
- Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg, Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg, Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg
- Where
- 3 sites in China
- Volunteers
- 26 people
- Sponsor
- CStone Pharmaceuticals
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
This phase IIb trial tests the effect of HRX215 in treating patients with colorectal cancer that has spread from where it first started to the liver (liver metastasis) after undergoing a portal vein embolization (PVE).
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07612007
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma
Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
This is a multicenter, Single-arm, Real-world Study to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combined with Tislelizumab (Triple Therapy) for patients with Hepatocellular…
- Trial name
- NCT06602011
- Testing
- TACE, Lenvatinib, combined with Tislelizumab group
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Fujian Provincial Hospital
Chronic Myeloproliferative Disorders, Leukemia
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004239
- Testing
- Compound 506U78
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatocellular Carcinoma
Analysis of Expression of Specific Markers in Hepatocellular Carcinoma
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these.
- Trial name
- NCT00858000
- Testing
- Retrospective analysis of already archived samples
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Hepatocellular Carcinoma (HCC)
TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion
This is a prospective, randomized study designed to compare the efficacy of transcatheter hepatic artery chemoembolization (TACE) combined with bevacizumab arterial perfusion versus conventional therapy in patients with…
- Trial name
- NCT07075562
- Testing
- Bevacizumab Arterial Perfusion plus TACE, Conventional Therapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The First Hospital of Hebei Medical University
Liver Cirrhosis, Refractory Ascites
ALFApump System Post Marketing Surveillance Registry
This is a post market surveillance registry to monitor the safety and performance of the ALFApump system.
- Conditions
- Liver Cirrhosis, Refractory Ascites, Malignant Ascites
- Trial name
- 2011-AAR-004 (NCT01532427)
- Where
- 13 sites in Germany, Spain and 2 more
- Volunteers
- 100 people
- Sponsor
- Sequana Medical N.V.
Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
Hepatocellular carcinoma (HCC) is the fourth most common cancer in China, with a crude incidence rate of 26.67 per 100,000 population. Moreover, 357,800 new liver cancer cases are predicted to be diagnosed in China in 2020.
- Trial name
- NCT04127396
- Testing
- Lenvatinib Pill, Transarterial chemoembolization(TACE), Sorafenib
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Ditan Hospital
Advanced Breast Carcinoma, Advanced Endometrial Carcinoma
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients with solid tumors involving the…
- Conditions
- Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma
- Trial name
- NCT05092373
- Testing
- Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Malignant Tumors
Histotripsy for Ablation of Liver Tumours in Asia
The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease.
- Trial name
- HALT (NCT07428356)
- Testing
- Histotripsy using HistoSonics Edison™ System
- Where
- 3 sites in Singapore
- Volunteers
- 40 people
- Sponsor
- National Cancer Centre, Singapore
Hepatocellular Carcinoma
Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these.
- Trial name
- NCT00911196
- Testing
- Retrospective analysis of already archived samples
- Where
- 3 sites in Taiwan, Thailand
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Liver Cancer
Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma
Objectives: The purpose of this study is to evaluate the safety and efficacy of radical surgery combined with dendritic cell-precision multiple antigen T cells in reducing the recurrence and metastasis of liver cancer Methods…
- Trial name
- NCT02632188
- Testing
- Postoperative routine treatment, DC-PMAT treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Military Medical University
Hepatocarcinoma, Pancreatic Tumor
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors
Hepatic (hepatocellular carcinoma (HCC)) and pancreatic (pancreatic adenocarcinoma (ADKP); pancreatic neuroendocrine tumors (TNEP)) primary tumors are the most common malignant tumors of the hepato-bilio-pancreatic system and…
- Trial name
- PROMETHEP (NCT05794048)
- Testing
- Hepatocellular carcinoma, Pancreatic adenocarcinoma, Pancreatic neuroendocrine tumor
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma.
- Trial name
- NCT01754987
- Testing
- Ascorbic Acid + Sorafenib, Sorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Jefferson University
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of hepatic impairment.
- Trial name
- NCT02301104
- Testing
- TAS-102
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Taiho Oncology, Inc.
Cancer, Solid Tumor
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system.
- Conditions
- Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases
- Trial name
- CAT_PB (NCT06065592)
- Testing
- Palbociclib, Rivaroxaban, SNP
- Where
- 2 sites in Lebanon
- Volunteers
- 500 people
- Sponsor
- Lebanese University
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01638533
- Testing
- Pharmacological Study, Romidepsin
- Where
- 12 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms Malignant
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy.
- Trial name
- TACE-Ax-HCQ (NCT04873895)
- Testing
- Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Esophagus Cancer, Bladder Cancer
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Phase Ia: single-dose escalation study: accelerated titration combined with traditional "3+3" dose. Sample size is correlated with the DLT occurring in each dose group.
- Conditions
- Esophagus Cancer, Bladder Cancer, Liver Cancer, Ovarian Cancer
- Trial name
- NCT05829057
- Testing
- Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal Antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Zhejiang University